Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27514
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grigoriadis G. | en |
dc.contributor.author | Banerjee A. | en |
dc.contributor.author | Vasanthakumar A. | en |
dc.date.accessioned | 2021-05-14T09:15:46Z | en |
dc.date.available | 2021-05-14T09:15:46Z | en |
dc.date.copyright | 2013 | en |
dc.date.created | 20130613 | en |
dc.date.issued | 2013-06-13 | en |
dc.identifier.citation | Immunology and Cell Biology. 91 (5) (pp 340-349), 2013. Date of Publication: May-June 2013. | en |
dc.identifier.issn | 0818-9641 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/27514 | en |
dc.description.abstract | Regulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy. © 2013 Australasian Society for Immunology Inc. All rights reserved. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | en |
dc.title | Modulating T regulatory cells in cancer: How close are we?. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/icb.2013.12 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 23567897 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23567897] | en |
dc.identifier.source | 52530948 | en |
dc.identifier.institution | (Banerjee, Vasanthakumar, Grigoriadis) Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Clayton, VIC 3168, Australia (Vasanthakumar) Molecular Immunology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia (Grigoriadis) Department of Clinical Haematology, Central Clinical School, Monash University, Clayton, VIC, Australia (Grigoriadis) Department of Clinical Haematology, Monash Health, Clayton, VIC, Australia | en |
dc.description.address | A. Banerjee, Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Clayton, VIC 3168, Australia. E-mail: ashish.banerjee@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2014 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | cancer immunotherapy T regulatory cells | en |
dc.identifier.authoremail | Banerjee A.; ashish.banerjee@monash.edu Vasanthakumar A.; vasanthakumar@wehi.edu.au Grigoriadis G.; george.grigoriadis@monash.edu | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.